北美粘液补充市场 – 行业趋势和 2029 年预测

北美粘液补充市场分析与洞察

预计北美粘液补充市场将在 2022 年至 2029 年的预测期内增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 8.7%。北美医疗保健领域粘液补充治疗的技术进步是推动北美粘液补充市场在预测期内增长的另一个因素。

然而，治疗费用高昂，以及暂时注射、部位疼痛、肿胀、发热和红肿等副作用将限制市场的增长。主要市场参与者建立合作伙伴关系和收购等战略联盟，为北美粘弹性补充市场的增长提供了机会。

市场定义

The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.

Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market. 

Market Dynamics                                        

Drivers

• Rising geriatric population

With this increasing age comes a reciprocal increase in the elderly patients admitted to the hospitals due to fatal traumatic injuries. The rising prevalence of knee osteoarthritis diseases leads to increasing demand for diagnosis and treatment. With the growing population, the pressure on the healthcare system is rising. The increasing need for the proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as sarcopenia, osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. In such patients, viscosupplementation is used in the procedure to provide them with immediate and efficient benefits associated with their bodies.

With this increasing age and rising prevalence of osteoarthritis, the demand for early diagnosis of the diseases is also increasing. Therefore, the demand for viscosupplementation is rising for the treatment in the healthcare system across the globe.

• Increasing risk of osteoporosis and osteoarthritis

Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease is silent and typically shows no symptoms. Mostly elderly people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.

The silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone, among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the North America viscosupplementation market.

Restraint

• Lack of technical expertise

Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but this number is much less across the globe as these procedures are complex.

However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.

Thus, the lack of technical expertise may act as a restraint for the market's growth.

Opportunity

• Safety and effectiveness of intra-articular hyaluronic acid (IAHA)

There are several types of hyaluronic acid injections, also called viscosupplementation, which are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a US Food and Drug Administration-approved treatment for knee osteoarthritis (OA). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.

Challenge

• Stringent government policies for THE USE OF viscosupplementation

The commercialization of viscosupplementation across the globe by various key market players is facilitated by compliance with the regulatory frameworks established by many countries across the globe. The pre-market approval of various medical devices varies from one country to another. The U.S. Food, Drug, and Cosmetic Act ("FD&C Act") classify medical devices in the U.S. The European Union (EU) regulates medical devices in Europe. However, the rapid development of privacy policies and regulations are being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia.

The viscosupplementation is regulated by a structure of laws, rules, and regulations that are extensive and complex to safeguard them from use in any potential harmful treatment.

The viscosupplementation act as a replacement for the damaged, injured, or infected body parts in cases of osteoarthritis conditions or sports accidents among patients, along with maintaining the patient's demand for good body movement. However, any misguidance will affect the patient's safety and body structure.

Therefore, the stringent rules & regulations for the use of viscosupplementation may act as a challenge to the growth of the market.

Post-COVID-19 Impact on North America Viscosupplementation Market

COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to impact the North America viscosupplementation market greatly.

North America Viscosupplementation Market Scope and Market Size

North America viscosupplementation market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.

BY SOURCE

• ANIMAL ORIGIN
• NON-ANIMAL ORIGIN

On the basis of source, the viscosupplementation market is segmented into the animal origin and non-animal origin.

BY MOLECULAR WEIGHT

• HIGH MOLECULAR WEIGHT
• LOW MOLECULAR WEIGHT
• INTERMEDIATE MOLECULAR WEIGHT

On the basis of molecular weight, the viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.

BY INJECTION

• SINGLE INJECTION
• THREE INJECTION
• FIVE INJECTION

On the basis of injection, the viscosupplementation market is segmented into single injection, three injections, and five injections.

BY AGE GROUP

• ADULTS
• GERIATRICS

On the basis of age group, the viscosupplementation market is segmented into geriatric and adults.

END-USER

• HOSPITALS
• ORTHOPEDIC CLINIC
• HOME HEALTHCARE
• OTHERS

On the basis of end-user, the viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others.

BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES

On the basis of distribution channel, the viscosupplementation market is segmented into direct tender and retail sales.

Viscosupplementation Market Country Level Analysis

The viscosupplementation market is analyzed, and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.

The countries covered in the North America viscosupplementation market report are U.S., Canada, Mexico, Panama, Jamaica and the Dominican Republic.

In 2022, the U.S. is dominating due to the growing preference for alternative corticosteroids for joint pain management treatment options. The U.S is expected to grow due to the rise in technological advancement in drug treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

North America viscosupplementation market also provides you with a detailed market analysis of every country growth in the healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, the impact of regulatory scenarios, and trending parameters regarding the North America viscosupplementation market.

Competitive Landscape and North America Viscosupplementation Market Share Analysis

North America Viscosupplementation market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to viscosupplementation treatments.

The major companies which are dealing in the viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.P.A, Ferring B.V,  sanofi-aventis U.S. LLC, Zimmer Biomet, OrthogenRx, Inc. (a subsidiary of AVNS),  APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), among others

Strategic alliances like mergers, acquisitions, and agreements by the key market players are further expected to accelerate the growth of viscosupplementation treatments.

For instance,

• In May, 2022, Fidia Farmaceutici S.p.A.  harnesses the regenerative power of hyaluronic acid with its innovative portfolio launched in Spain

Fidia Farmaceutici S.p.A. presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. The company has launched its complete Hyal System and Hy-Tissue portfolio in Spain. This has helped the company to showcase its research for hyaluronic acid

• In June 2022, Johnson & Johnson announced new data from Phase 3 studies demonstrating patients treated with medicine achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis,b spinal pain, and disease severityc endpoints – irrespective of baseline characteristics. This has helped company to showcase its progress
• 2021 年 11 月，LG 化学启动了新一代骨关节炎治疗药物的临床开发。LG 化学宣布，基于骨关节炎治疗新药候选药物 LG00034053 的临床前阳性结果，该公司已获得韩国食品药品安全部 1b/2 期临床试验的批准。LG 化学计划通过设计连接 1 期和 2 期的临床试验来加速新药的开发。

这有助于该公司开发治疗骨关节炎的新药

• 2020 年 11 月，Viatris Inc. 成功整合了迈兰公司 (Mylan NV) 和辉瑞公司 (Pfizer) 的 Upjohn 业务。通过整合这两家互补的传统公司，Viatris 拥有科学、制造和分销专业知识，以及经过验证的监管、医疗和北美商业能力，可为 165 多个国家和地区的患者提供高质量的药品。这有助于该公司扩大业务。

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在北美粘液补充市场的影响力，这也有利于该组织的利润增长。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68854